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Acylglycines are an important class of metabolites that have been used in the diagnosis of
several inborn errors of metabolism (IEM). However, current analytical methods detect only a
few acylglycines. There is a need to profile these metabolites in a comprehensive manner for
studying their functions and improving their diagnostic values for different IEM and
potentially other diseases. We describe a sensitive method that combines the chromatographic
resolving power of ultra-performance liquid chromatography (UPLC) to separate closely
related metabolites including isomers with tandem mass spectrometry (MS/MS). Acylglycines
were extracted from urine using an anion exchange solid-phase extraction (SPE) cartridge.
After UPLC separation, the acylglycines were detected on a hybrid triple quadrupole linear ion
trap mass spectrometer. A set of standards were used for the development of an optimal MS
acquisition method. Several acquisition modes using information derived from collision-
induced dissociation breakdown curves were used to detect acylglycines. Using this method,
18 acylglycines were detected in the urine of healthy individuals and confirmed using
standards, while 47 additional acylglycines were detected and tentatively identified, based on
their retention and fragmentation pattern. Among the 65 acylglycines detected, only 18 of them
have been previously reported in biofluids of healthy individuals. These results will be
deposited in a public human metabolome database. This example illustrates that by develop-
ing a method tailored to the analysis of a class of metabolites sharing similar structural
moieties, we can potentially identify many more new metabolites, thereby expanding the
overall metabolome coverage. (J Am Soc Mass Spectrom 2010, 21, 2105–2116) © 2010
American Society for Mass SpectrometryMetabolomics is an emerging field that is poisedto play a significant role in many disciplinesof biosciences. One of the current challenges
in metabolomics is to profile the metabolome in a very
comprehensive manner, ideally covering the entire set
of metabolites present in a biological system. However,
due to technical limitations, only a small portion of the
metabolome is analyzed. There is a great need to expand
the metabolome coverage to reveal subtle changes of the
metabolome in biological studies or disease biomarker
discovery. Liquid chromatography mass spectrometry
(LC/MS) is a sensitive technique that can detect many
metabolites in a metabolome sample [1]. However,
metabolite identification from the mass spectral data
alone is often difficult [2–6]. There are only a limited
number of metabolite standards available for spectral
comparison to identify unknowns. For example, in the
Human Metabolome Database (HMDB), product ion
spectra of about 900 known standards obtained by
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doi:10.1016/j.jasms.2010.09.004tandem mass spectrometry (MS/MS) are included. To
create this MS/MS spectral library, we went through
almost all the possible commercial sources to acquire
the available metabolite standards [7]. This number is
still quite small compared to the size of the human
metabolome; the total number of human metabolites is
unknown, but the HMDB contains over 8000 entries of
endogenous human metabolites. We need to expand
this spectral library to include many more metabolites
found in biological sources, such as human biofluids. A
comprehensive metabolite spectral library will enable
many metabolomics researchers to take advantage of
the database resource for identifying metabolites for
biological studies or biomarker discovery.
We are currently pursuing a strategy to expand the
metabolome coverage and the spectral library by sys-
tematically detecting and identifying metabolites shar-
ing one or more similar structural moiety, such as
glycine. Because some standards from this group are
available, analyzing the unknown metabolites of the
same group becomes more manageable. In this work,
we demonstrate the development and application of
this strategy to detect and identify unknown acylgly-
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lites that have been used in the diagnosis of several
inborn errors of metabolism (IEM) [8].
IEMs are inherited disorders that are due to gene
defects coding specific enzymes involved in the metab-
olism of amino acids or organic acids [8]. One of the
main classes of IEMs consists of disorders of fatty acid
oxidation and mitochondrial metabolism. In individu-
als with fatty acid oxidation disorder, a wide array of
symptoms is due to the toxic fatty acid acyl-coA esters
that accumulate in the mitochondria. Glycine conjuga-
tion with these acyl-coA esters has been of clinical
interest due to their role in the detoxification process.
Increased concentration of urinary acylglycines is gen-
erally indicative of IEMs [9–11].
The most widely used analytical methods for deter-
mining acylglycines in urine include solvent extraction,
derivatization, followed by separation and detection
using gas chromatography mass spectrometry (GC-MS)
[12–17]. Although this established method offers many
advantages, it requires specific derivatization reactions
for analyzing the polar acylglycines. Also diagnoses of
some IEMs can be challenging due to the relatively low
sensitivity of the analytical process [18]. The application
of tandem mass spectrometry (MS/MS) has been used
as an alternative to GC-MS and as a high-throughput
method. Analysis by fast atom bombardment (FAB) and
lately electrospray ionization (ESI) have been well doc-
umented [19–22]. Although these methods can detect a
larger number of disorders in a single run, they lack the
ability to distinguish between isomers and detect rela-
tively low abundance acylglycines, thus may not be able
to distinguish between certain disorders [22].
We report a LC-MSmethod based on the use of triple
quadrupole linear ion trap (QTRAP) mass spectrometer
that offers higher sensitivity and more data-dependent
scanning modes than a conventional triple quadrupole
tandem mass spectrometer [23]. Separation is carried
out by using ultra-performance liquid chromatography
(UPLC), which allows for high-resolution separation of
isomers and closely related acylglycines. The aim of this
work is to identify as many unknown acylglycines as
possible to expand the overall molecular coverage of
this important class of metabolites. We show that the
described method provides a sensitive analytical proce-
dure to detect previously undetected acylglycines in the
urine of healthy individuals; 65 acylglycines were
found using the newmethod, compared to the currently
known 18 compounds.
Experimental
Chemicals and Reagents
All chemicals except those noted were purchased from
Sigma-Aldrich Canada (Oakville, ON, Canada). Human
pooled liver microsomes and nicotinamide adenine
dinucleotide phosphate (NADPH) regeneration solu-
tions A and B were purchased from BD Gentest(Franklin Lakes, NJ, USA). Optima grade methanol
and water, Optima LCMS grade acetonitrile, and
acetic anhydride and pyridine were purchased from
Fisher Scientific (Ottawa, ON, Canada). HPLC-grade
formic acid and ammonium hydroxide were obtained
from Fluka (Milwaukee, WI, USA). The standard
acylglycines used were dimethylglycine, phenylgly-
cine, acetylglycine, propionylglycine, isobutyrylgly-
cine, butyrylglycine, 4-hydroxyphenylacetylglycine,
2-methylbutyrylglycine, isovalerylglycine, valerylg-
lycine, tiglyglycine, 3-methylglycine, suberylglycine,
glutarylglycine, phenyacetylglycine, phenylpropio-
nylglycine, hexanoylglycine, octanoylglycine, and
hippuric acid.
Samples
Urine was collected from six healthy volunteers who
were not on any special diet. An informed consent was
obtained from the volunteer and ethics approval for this
work was obtained from the University of Alberta in
compliance with the University Health Information Act.
The volunteers were all adults, ranging in age from 24
to 38 y old. The urine samples were collected as first
morning void samples for all six volunteers and urine
was also collected over 12 h for two of those individu-
als. The samples were centrifuged, aliquoted, and
stored at 20 °C without any preservatives added until
analysis. For long-term storage, the samples were kept
at 80 °C.
Microsome Incubation
Acylglycines standards (50 M) were individually in-
cubated with human liver microsomes (2 mg/mL) in
100 mM potassium phosphate, pH 7.4. The standards
were first pre-incubated at 37 °C for 5 min, followed by
the addition of NADPH regenerating solution, contain-
ing components A (26.1 mM NADP, 66 mM glucose-
6-phosphate, and 66 mM MgCl2 in H2O) and B (40
U/mL glucose-6-phosphate dehydrogenase in 5 mM
sodium citrate) in 100 mM potassium phosphate, pH
7.4. The solutions were incubated, with shaking, in a
37 °C incubator for periods of 30 min, 1, 3, 6, and 24 h.
Control incubations omitting either standards, NADPH
regenerating solution or microsomes were also per-
formed by substituting an equal volume of potassium
phosphate buffer. The reactions were then terminated
by the addition of 5% acetic acid in acetonitrile (vol/
vol). The samples were centrifuged at 14,000 g for 5 min
and the supernatants were subjected to solid-phase
extraction (SPE).
Solid Phase Extraction
Oasis mixed-mode anion exchange (MAX) cartridges
(Waters, Mississauga, ON, Canada) were operated at a
flow rate of 1 mL/min using a vacuum manifold
(Alltech from Fisher Scientific, Ottawa, ON, Canada).
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with 1 mL acetonitrile followed by equilibration with 1
mL water. Urine (1 mL) was loaded onto the columns
and the columns were washed with 1 mL 5% ammo-
nium hydroxide solution. Acylglycines were eluted in
two fractions, 1 mL 2% formic acid in 40% acetonitrile/
60% water followed by 1 mL 2% formic acid in aceto-
nitrile. The eluents were evaporated to dryness, using a
vacuum centrifuge concentrator, and reconstituted in
100 L 4% acetonitrile, 0.1% formic acid in water.
Samples extracted were urine, urine spiked with stan-
dards, and microsomal incubations.
Esterification
To confirm the identification of acylglycines found,
methylation and acetylation were performed [20]. These
reactions were optimized using standards and con-
firmed to be useful in assisting in compound identifi-
cation. For the urine samples, after extraction of the
samples by SPE, the eluents were evaporated to dryness
in a vacuum centrifuge concentrator. Three hundred
microliters of 3 M methanolic HCl was added to the
dried extract in a reaction vial and allowed to react at
65 °C for 15 min. The reaction mixture was then divided
into two equal portions; one portion was evaporated
under a stream of nitrogen and reconstituted in 100 L
10:90 acetonitrile:water (vol/vol), 0.1% formic acid. The
other portion was also evaporated under a stream of
nitrogen and treated with 100 L of 50:50 acetic anhy-
dride/pyridine (vol/vol) and allowed to react at room
temperature for 1 h. The solvents were evaporated
under a stream of nitrogen and the residue was recon-
stituted in 100 L 10:90 acetonitrile:water, 0.1% formic
acid.
UPLC Separation
Chromatographic separation was done on a Waters
ACQUITY UPLC system with a 1.7-m bridged ethyl-
ene hybrid (BEH), 150 mm  1.0 mm C18 column. The
column was maintained at ambient temperature. Elu-
tion was done according to the following method: 100%
A for 11 min, then a linear gradient of 0–35% B over 50
min, 35%–100% B over 5 min, and held at 100% B for 9
min, where mobile phase A consisted of 4% acetonitrile,
0.1% formic acid in water, and B consisted of 0.1%
formic acid acetonitrile. The flow rate of the method
was 0.050 mL/min and 5.0 L of each sample was
injected onto the column.
Mass Spectrometry
Mass analysis was carried out in an ABI 4000 QTRAP
mass spectrometer equipped with a TurboIonSpray
source (Applied Biosystems, Foster City, CA, USA). The
UPLC and mass spectrometer were both controlled by
Analyst software ver.1.5 from Applied Biosystems. The
mass spectrometer was operated in both positive andnegative electrospray ionization (ESI) mode. General
mass spectrometric conditions were: for positive mode,
spray voltage, 4800 V; temperature, 200 °C; GS1, 40;
GS2, 10; curtain gas, 10; CAD, high; declustering poten-
tial, 35; collision energy, 22 eV; for negative mode: spray
voltage,3100 V; temperature, 200 °C; GS1, 40; GS2, 10;
curtain gas, 10; CAD, high; declustering potential, 40;
collision energy, 20 eV. The acquisition method con-
sisted of several information dependent acquisition
(IDA) scan cycles including precursor ion, constant
neutral loss or multiple reaction monitoring (MRM) as
the survey scan and four dependent enhanced product
ion (EPI) scans. IDA criteria were set to allow the four
most intense peaks to trigger the EPI scans. The EPI
scans were in the range of 50–500 Da, scanned at 250,
1000, and 4000 Da/s and source parameters were the
same as mentioned above. The total duty cycle was
1.2 s. Data were collected in profile mode and ana-
lyzed using Analyst ver. 1.5 and LightSight ver. 2.0.
Breakdown Graphs and Scan Modes
To obtain optimal conditions for the detection of acyl-
glycines, breakdown curves from collision-induced dis-
sociation (CID) of precursor ions were constructed.
Solutions of each acylglycine standard were dissolved
in water at a concentration of 0.5 mM and stored at
20°C. These solutions were diluted to 10 M in a
mixture of CH3CN/H2O (50:50), 0.1% formic acid and
infused into the ion source with a syringe pump at a
rate of 10 L/min. Product ion spectra were obtained
from the precursor ion in the positive mode by averag-
ing 30 cycles. Scans were performed at different colli-
sion energies ranging from 5 to 40 eV, with a step size
of 5 eV.
Based on the information obtained from the break-
down curves, appropriate neutral loss and precursor
ion scans were performed as survey scans in IDA
experiments, which triggered four dependent EPI
scans. MRM transitions were set up based on masses of
acylglycines that were detected in the neutral loss and
precursor ion scans and those acylglycines likely to be
found in urine but whose signals were too low to be
detected by the constant neutral loss and precursor ion
scans. IDA experiments were created with these MRM
transitions as a survey scan, in an experiment similar to
the precursor and neutral loss methods.
Results and Discussion
Sample Handling Issues
The main purpose of this work was to develop a means
of detecting as many acylglycines as possible. We thus
optimized each step of the analysis procedure to max-
imize the performance of the technique. For example,
current methods of extracting acylglycines from urine
include liquid-liquid extraction followed by derivatiza-
tion [12, 13]. However, human urine is a complex
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pounds, peptides and proteins. In this work, a more
selective sample extraction method was developed. To
optimize the solid-phase extraction procedure, two car-
tridges, hydrophilic-lipophilic balanced (HLB) and
mixed-mode anion-exchange (MAX) cartridges, were
tested. Factors to optimize the conditions include com-
position, volumes and pH of the wash and eluting
solutions (data not shown). MAX cartridge was chosen
based on its high selectivity in retaining the acylgly-
cines. The optimal conditions are listed in the experi-
mental section. This method was found to be effective
in isolating acylglycines and organic acids from human
urine; for acylglycine standards, recoveries of greater
than 88% were obtained. The extraction method was
also reproducible. As an example, four urine samples
were extracted using four different SPE cartridges and
were injected into the UPLC to compare the perfor-
mance of the different MAX cartridges. The results
shown in Supplemental Figure S1, which can be found
in the electronic version of this article, indicate excellent
cartridge-to-cartridge reproducibility, signifying the ro-
bustness of the extraction procedure.
Another improvement is in the area of LC separa-
tion. Instead of HPLC, UPLC was used in this work.
UPLC capitalizes on the use of sub-2-m particles to
offer superior efficiency and resolution compared to
HPLC [24]. The higher efficiency translates into better
detection sensitivity with narrower peaks which in-
creases the detectability of acylglycines present in low
concentrations in urine. The higher resolution is signif-Scheme 1. Proposed fragmentatiicant in separating isomeric and isobaric species. It was
found that the UPLC method used was efficient in
separating the isomers of acylglycines, which is very
important in aiding the assignment of potential struc-
tures to unknown acylglycines. An example of the
high-resolution separation is shown in Supplemental
Figure S2. Baseline separation can be observed for all
isomers of C5 and C5:1. In contrast, HPLC could not
resolve these peaks well and some of the low intensity
peaks were not observed (data not shown).
MS Fragmentation Patterns of Standards
Analyzing the MS fragmentation patterns of available
standards can facilitate the development and optimiza-
tion of a MS/MS method for sensitive and selective
detection of a group of similar compounds including
unknowns. In this work, seventeen acylglycines were
used to generate the MS/MS fragmentation informa-
tion. The fragmentation pathways of acylglycines are
shown in Scheme 1 and the pathways of the glycine-
conjugated dicarboxylic acids (DCs) are shown in Sup-
plemental Scheme S1. As these schemes show, common
neutral losses of masses 18 (H2O), 46 (H2O  CO), 75
(NH2CH2COOH), and 103 (NH2CH2COOH  CO) are
observed for most of the acylglycines. Less common
fragments observed are the neutral losses of 60 (CH2 
C(OH)2), 93 (NH2CH2COOH  H2O), observed in
straight chain acylglycines longer than six carbons and
117 (CH2  C(OH)NHCH2COOH), which is observed
as a major fragment in phenypropionylglycine, result-on pathways of acylglycines.
2109J Am Soc Mass Spectrom 2010, 21, 2105–2116 UPLC-MS/MS DETECTION OF ACYLGLYCINESing in the stable tropyllium ion. Many acylglycines also
show a major fragment ion at m/z 76, which corre-
sponds to the protonated glycine (H3
NCH2COOH).
This fragmentation pathway occurs because aliphatic
acylglycines lose the acyl moiety as a ketene. There
must be an available proton on carbon 2 of the acyl
group in order for this fragmentation to occur [19].
Fragmentation in QTRAP can be induced either
inside the linear ion trap or in the collision cell in the
triple quadrupole mode. The instrument is capable of
all the scans common to the triple quadrupole instru-
ment, such as precursor scanning (PC), constant neutral
loss scanning (NL) and multiple-reaction monitoring
(MRM), as well as trap scan modes enhanced product
ion (EPI), enhanced mass (EMS), and enhanced resolu-
tion (ER) scans. The instrument can also perform both
quadrupole and trap scans in a single run and switch-
ing from one to the other only takes a few ms. This can
be done in an information dependent data acquisition
(IDA), which combines two or more scan modes in a
single LC-MS/MS run. The mass spectrometer switches
from the first scan or a survey scan usually done as an
MS scan to a second data dependent MS/MS scan when
an eluting peak rises above a predetermined threshold
level. In this work, MRM, constant neutral loss scanning
and precursor scanning were used as survey scans with
the enhanced product ion scans as the dependent
MS/MS scans.
Currently, all acylglycines detected by direct infu-
sion ESI-MS/MS use a precursor of m/z 76 method or if
methylation is done, a precursor of m/z 90 method [20].
In our work, the optimal energetic conditions for the
Figure 1. Breakdown graphs of (a) valerylglyc
phenylpropionylglycine. Fragmentation studies
Low-energy CID was performed with nitrogen
optimized and operating conditions were as fol
temperature  200 °C; GS1  40; GS2  10; curtaindetection of acylglycines were obtained from the break-
down curves. The best choice for collision energy and
MRM transitions can be readily observed from these
curves. A typical breakdown curve in this work is
shown in Figure 1a for valeryglycine. Most of the
typical losses (as shown in Scheme 1) are observed. At
low to medium collision energy (15  CE  30), the
most abundant fragment ion is m/z 76 and at high
collision energy (CE  30), the fragment ion corre-
sponding to the loss of 103 is the most abundant.
Although most acylglycines yield a fragment at m/z
76, not all of them do. The breakdown curve of tigly-
cine, shown in Figure 1b, demonstrates this. The major
loss observed is the loss of 75 Da, the neutral glycine
moiety. No fragment ion at m/z 76 is generated because
there is no available proton on carbon 2 of the acyl
group [19, 22]. An IDA method, which uses a survey
scan of neutral loss of 75, should be used to detect
acylgycines, including tiglyglycine, 3-methycrotonylglycine,
hippuric acid, and hydroxyhippuric acid isomers,
among others. These acylglycines would not be de-
tected using a precursor of m/z 76 method. Therefore
the optimal transition for MRM is precursor ion frag-
mentation corresponding to the loss of 75 Da.
It is important to note that the fragment ion at m/z 76
may not be the most intense fragment in the product ion
spectra and if this transition is used in detection,
sensitivity is lost. Examples of this are shown in Figure
1c and d. Breakdown curves of aromatic acylglycines
reveal that the neutral loss of 103 is the most abundant
fragment and not the fragment at m/z 76. The optimal
conditions for the detection of aromatic acylglycines at
b) tiglyglycine, (c) phenylacetylglycine, and (d)
e performed using a 4000 QTRAP instrument.
the collision gas. The source parameters were
CAD gas  nitrogen; spray voltage  4800 V;ine, (
wer
as
lows:
gas  10; CAD  high; DP  35.
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to the fragment ion produced with the loss of 103 (e.g.,
for phenylacetylglycine, m/z 194 ¡ 91).
Other trends observed in the fragmentation of acyl-
glycines are the following: losses of 18 and 46 are
usually low in intensity and sometimes not observed,
especially in aromatic glycines and glycines conjugated
to unsaturated fatty acids. Fragment ion m/z 76 is the
major fragment for straight and branched chain acylg-
lycines. Loss of 103 is more intense in branched chains
than in straight chains, especially when it is branched at
the 2-position of the fatty acid chain. For the glycine
conjugates of dicarboxylic acid, the fragment ion at m/z
76 is not the major product ion. In this case, loss of 64
fragment ion is the most abundant fragment ion at a CE
of 20 eV. Losses of 18 and 46 are higher in intensities
than in the acylglycines.
MS Scan Modes for Sample Analysis
Because most acylglycines yield an intense fragment ion
at m/z 76 in the positive mode, an IDA experiment was
performed using precursor scanning as a survey scan
followed by enhanced product ion scan as the data de-
pendentMS/MS scan. Acylglycines also possess a carbox-
ylic acid group, so they can be analyzed in the negative
ionization mode. In the negative ion mode they lose the
deprotonated glycine moiety (H2NCH2COO
, m/z 74). A
similar IDA experiment was performed with a precursor
of m/z 74 scan as the survey scan. A comparison of the
positive and negative precursor scans is shown in
Figure 2a,b. Negative ion scan did not significantly
improve the selectivity and sensitivity in comparison to
the positive mode. Most acylglycines were detected in
both modes and the overall intensities were quite
similar. Some acylglycines that do not generate a frag-
ment ion at m/z 76 will still generate the fragment ion at
m/z 74, such as tiglyglycine and 3-methycrotonylglycine.
Several earlier eluting peaks like acetylglycine, isobu-
tyrylglycine, butyrylglycine, and hydroxyphenylac-
etylglycine were detected at considerably higher inten-
sities using the positive ionization mode. Due to this
and the fact that positive MS/MS scans give much more
structural information than those acquired in negative
mode, all subsequent scans were done in the positive
ion mode.
As mentioned earlier, some acylglycines do not frag-
ment to yield a product ion at m/z 76. However, all
acylglycines commonly lose the neutral glycine frag-
ment (a neutral loss of 75 Da) and the remaining acyl
fragment retains the positive charge. An IDA experi-
ment in the positive ionization mode, similar to that
described above, was performed, except the survey
scan used was a neutral loss of 75 Da scan. Figure 2c
shows a total ion chromatogram of an IDA experiment
using constant neutral loss of 75 Da as the survey scan. Acy-
lglycines such as hippuric acid, 3-methylcrotonylglycine,
tiglyglycine, phenylglycine, hydroxyhippuric acid,
and methylhippuric acid were not detected in theprecursor method and exhibited major fragment ions at
m/z 105, 83, 83, 77, 121 and 119, respectively, corre-
sponding to the neutral loss of 75 Da (see the Supple-
mental Data for all the MS/MS spectra of acylglycines).
Comparison of the TICs shown in Figure 2b and c
shows that most of the acylglycines observed in the
precursor method were also found using the neutral
loss method. However, the neutral loss method was not
as selective because other classes of compounds that
gave the neutral loss of 75 Da (the identities of these
compounds were unknown) were also detected and
many acylglycines were detected at lower intensities.
When targeting certain compound families in biolog-
Figure 2. Ion chromatograms from UPLC MS/MS analysis of
healthy human urine: (a) TIC of precursor ion scanning of m/z 74
(negative mode), (b) TIC of precursor ion scanning of m/z 76
(positive mode), and (c) TIC of neutral loss scanning of 75 Da.
Urine sample from a healthy volunteer was analyzed using three
information dependent acquisition (IDA) methods of precursor
ion scans in the positive and negative modes and neutral loss scan
in the positive mode.ical matrices, high selectivity and sensitivity become
2111J Am Soc Mass Spectrom 2010, 21, 2105–2116 UPLC-MS/MS DETECTION OF ACYLGLYCINESvery essential. Precursor and constant neutral loss scans
are highly selective, but are only moderately sensitive.
A much better alternative is to use MRM as the survey
scan to trigger the enhanced product ion data collection.
MRM is much more selective and sensitive than either
precursor scanning or constant neutral loss scanning.
Due to the differences in the fragmentation of certain
acylglycines, specific MRM transitions were chosen for
each acylglycine using fragmentation information
gleaned from the precursor scanning and constant
neutral loss scanning methods and the breakdown
curves. The precursor scanning and constant neutral
loss scanning survey scans provided information about
the masses of all possible acylglycines that can be
observed and the breakdown curves were used to
provide the best possible transitions. These optimized
MRM transitions as well as dwell times and collision
energy are shown in Table 1. The survey scan contained
62 MRM transitions and each transition was performed
with a dwell time of 15 ms and a CE of 20 eV. The scan
time was 1.2 s for all transitions. The IDA intensity
threshold was set to 100 counts per second (cps) and the
dependent scans were performed in enhanced product
ion mode with a CE of 20 eV. Four enhanced product
ion scans were performed on the four most intense
peaks before switching back to MRM scan mode.
Table 1. MRM scanning conditions used in the analysis of acylg
Q1 (m/z) Q3 (m/z) Dwell time (ms) CE (eV)
104 58 15 20
118 76 15 20
146 76 15 20
152 77 15 20
158 83 15 20
160 76 15 20
162 76 15 20
170 95 15 20
172 75 15 20
172 69 15 20
174 76 15 20
176 76 15 20
176 64 15 20
180 105 15 20
181 106 15 20
184 109 15 20
186 76 15 20
186 83 15 20
188 76 15 20
188 95 15 20
190 76 15 20
190 126 15 20
194 91 15 20
194 119 15 20
196 121 15 20
198 76 15 20
198 95 15 20
200 76 15 20
200 97 15 20
202 76 15 20
202 109 15 20Human Urine Analysis
After the method was developed, we applied it to analyze
human urine samples using the 62 MRM transitions to
detect acylglycines. Figure 3 shows the ion chromatograms
obtained fromUPLCMS/MSof urine samples of six healthy
volunteers. Relative differences in intensities of acylgly-
cines can be observed. Most of acylglycines are common
to all six individuals with the exception of dimethylgly-
cine and 4-hydroxyphenylacetylglycine, which are only
detected in four and five individuals, respectively.
Acylglycine identification was confirmed using stan-
dards and tentative identification of other acylglycines
was done using retention time and class-specific frag-
mentation patterns. To identify an unknown acylgly-
cine, at least four of seven neutral losses must be
observed. Water loss is very common and not consid-
ered to be structurally valuable.
Due to the lack of standards, positive identification
of many unknown acylglycines cannot be made. We
have attempted to use the methods of human liver
microsome (HLM) metabolite production and chemical
derivatization to provide tentative identification for
some of the unknowns. In the HLM method, individual
acylglycine standards were incubated with human liver
microsomes to generate the metabolites of acylglycines
es in the positive ion mode
Q1 (m/z) Q3 (m/z) Dwell time (ms) CE (eV)
204 76 15 20
204 140 15 20
206 76 15 20
206 103 15 20
208 105 15 20
210 107 15 20
212 137 15 20
214 76 15 20
214 111 15 20
216 76 15 20
216 123 15 20
218 76 15 20
218 125 15 20
218 154 15 20
222 76 15 20
222 119 15 20
224 76 15 20
224 121 15 20
226 76 15 20
232 168 15 20
242 149 15 20
242 167 15 20
244 169 15 20
246 76 15 20
246 182 15 20
250 147 15 20
256 76 15 20
256 163 15 20
258 194 15 20
260 196 15 20lycin276 201 15 20
lunte
2112 LEWIS-STANISLAUS AND LI J Am Soc Mass Spectrom 2010, 21, 2105–2116potentially found in human urine. The hydroxylated
and carbonyl-substituted metabolites were the most
common metabolites observed in the microsome incu-
bations. A comparison of the retention times and frag-
mentation patterns of the metabolites was used to aid in
the identification of some of the unknown acylglycines.
An example of such a comparison is shown in Figure 4.
The ion chromatograms from microsome incubation
and urine are shown in Figure 4a and c, respectively.
Figure 4b shows the MS/MS spectrum from the chro-
matographic peak labeled with a diamond at the reten-
tion time of 21.11 min (Figure 4a). Figure 4d shows the
MS/MS spectrum from the peak with a diamond at the
retention time of 21.22 min (Figure 4c). The inset in
Figure 4d shows the fragmentation pattern of hydroxy-
phenylpropionylglycine. Comparison of the MS/MS
spectra shows losses of 18, 46, 75, 103 and 117 in the
spectrum of the urine sample. Losses of 18 and 46 (not
Figure 3. Ion chromatograms from UPLC MS
obtained by using multiple reaction monitoring
were collected as first morning void from six vodiagnostic) and the precursor ion are not observed inthe MS/MS spectrum of the microsome extract (possi-
bly too high CE), but losses of 75, 103, and 117 are
common to both, with the major fragment ion being the
loss of 117. Even though not all the fragment ions are
observed, the diagnostic losses are common. Compari-
son of retention time and MS/MS spectra allows for the
identification of hydroxyphenylpropionylglycine. It is
important to note that the isomers generated by the
microsomes are not necessarily the same isomers ex-
creted in urine but the isomeric information is nonethe-
less valuable.
Chemical derivatization is also useful for acylglycine
identification. We note that compounds other than
acylglycines can also produce a fragment ion of m/z 76
in the product ion scan. However, comparison between
underivatized urine and derivatized urine can assist in
identifying acylglycines and distinguish them from
other compounds. A shift of 14 Da in the precursor
analysis of six healthy human urine samples
s with 62 diagnostic transitions. Urine samples
ers eating normal diets./MS
scanmass (28 Da in the case of DCs), an appropriate shift in
xyph
2113J Am Soc Mass Spectrom 2010, 21, 2105–2116 UPLC-MS/MS DETECTION OF ACYLGLYCINESretention time and corresponding losses in the product
ion scans should be observed for acylglycines. For
example, C6:1 acylglycine, previously unreported in the
urine of healthy individuals, was confirmed as a acyl-
glycine by methylation and the results are shown in
Supplemental Figure S3.
We have detected a total of 65 acylglycines and they
are listed in Table 2 in three groups (positively identi-
fied, tentatively identified, and unknown structures).
Only 18 of them have been previously reported. All of
the acylglycines used in screening for fatty acid disor-
ders were detected with the exception of propionylgly-
cine. Propionylglycine was not observed in any of the
individuals but was detected in low levels in a spiked
urine sample (the concentration of the spiked propio-
nylglycine was 10 M); this compound appears to be
present in very low concentrations in urine of healthy
individuals.
The standard deviations of the chromatographic
retention times of acylglycines detected from different
individuals were calculated and also presented in Table
2. This information is useful for other users who use
similar separation conditions for analyzing these me-
tabolites. The MS/MS spectra of these compounds are
provided as Supplemental Material and will be depos-
ited to a free, public-accessible database (www.hmdb.
ca) [7]. This database has over 8000 entries of mainly
endogenous human metabolites, including MS/MS
spectra of about 900 metabolites.
While Figure 3 illustrates that many acylglycines can
be detected from urine samples of different individuals,
a similar number of acylglycines can also be detected
Figure 4. Comparison of extracted ion chromat
extracted frommicrosomes (a) and urine (c), and
in (d) shows the fragmentation pattern of hydrofrom urine samples of an individual collected at differ-ent time points. This is illustrated in a preliminary work
where we examined the effect of the time of sampling
on the acylglycine profile of urine. For urine sample
collection, the most common type of collection is the
first morning voiding. Often a sample is collected
during fasting because analytes of interest may be
excreted in higher concentrations. However, other con-
ditions that occur in fasting can lead to an abnormal
excretion of other metabolites. In this study, urine was
collected from a healthy individual at the first morning
voiding, for five consecutive days (to assess the effect of
diet), at 4 h after a heavy meal and also was collected
over 12 h. Figure 5 shows the ion chromatograms of
urine collected at the first morning voiding from an
individual from five consecutive days. An overlay of
total ion chromatograms of multiple reaction monitor-
ing scans using 62 diagnostic transitions is shown. The
ion chromatograms of other urine samples collected are
shown in Supplemental Figure S4. Results of this com-
parison study revealed very little differences in the
acylglycine profile. Relative intensities may differ be-
tween time collections but the same acylglycines were
detected in all the time collections.
The above examples demonstrate that a large
number of acylglycines can be consistently detected
from urine samples collected from different individ-
uals or from the same individual at different times.
Thus, the developed method should be suitable for
profiling many acylglycines for potential discovery of
new biomarkers for IEMs and other diseases by using
a large pool of samples with clinical information on
s of m/z 224 (hydroxyphenylpropionylglycine)
sponding MS/MS spectra, (b) and (d). The inset
enylpropionylglycine.ogram
correthe individuals. Work in this direction is planned.
2114 LEWIS-STANISLAUS AND LI J Am Soc Mass Spectrom 2010, 21, 2105–2116Table 2. A list of confirmed and tentatively identified acylglycines present in urine of six healthy volunteers (n  6)*
Confirmed acylglycines (n  6) m/z RT (min) References
Acylglycine
Dimethylglycine‡ 104 2.12  0.0 [25, 26]
Phenylglycine 152 2.26  0.06
Acetylglycine 118 2.37  0.06 [19, 20]
Isobutyrylglycine 146 5.44  0.13 [13, 27]
4-Hydroxyphenylacetylglycine† 210 10.22  0.18
2-Methylbutyrylglycine 160 11.12  0.12 [13, 28, 29]
Tiglyglycine 158 11.89  0.19 [14, 30–32]
Isovalerylglycine 160 12.86  0.16 [13, 14, 17, 33, 34]
3-Methylcrotonylglycine 158 12.97  0.19 [14, 30, 35]
Valerylglycine 160 16.38  0.18
Hippuric acid 180 22.21  0.04 [15, 30, 36–38]
Suberylglycine 232 25.43  0.06 [13, 17]
Phenylacetylglycine (PAG) 194 25.88  0.06 [20]
Hexanoylglycine 174 30.07  0.04 [13, 14, 17, 19]
Phenylpropionylglycine (PPG) 208 33.88  0.04 [13]
Octanoylglycine 202 51.16  0.03
Tentatively identified acylglycines
Malonylglycine/hydroxybutyrylglycine (or isomers)† 162 2.59  0.05
Succinylglycine/hydroxyvalerylglycine (or isomers) 176 4.42  0.14
Dihydroxyhippuric acid (hydroxyls positions unknown) 212 5.27  0.06
Dihydroxyhippuric acid (hydroxyls positions unknown) 212 6.98  0.22
2-Furoylglycine 170 7.20  0.19 [30, 38, 39]
Dihydroxyhippuric acid (hydroxyls positions unknown) 212 8.24  0.27
Hydroxyhippuric acid (hydroxyl position unknown) 196 8.77  0.06 [21, 30, 40 43]
Dihydroxyhippuric acid (hydroxyls positions unknown) 212 10.85  0.23
Hydroxyhippuric acid (hydroxyl position unknown) 196 10.91  0.26 [21, 30, 32 40]
Hydroxyhexanoylglycine (hydroxyl position unknown) 190 11.61  0.16
2-Pentenoylglycine 158 13.85  0.17
Hydroxyhippuric acid (hydroxyl position unknown) 196 14.19  0.27 [30, 40]
Nicotinuric acid 181 15.03  0.21 [41, 42]
Hydroxyphenylacetylglycine† (hydroxyl position unknown) 210 15.74  0.26
Hydroxyphenylpropionylglycine (hydroxyl position unknown) 224 21.37  0.16
Hydroxyphenylpropionylglycine (hydroxyl position unknown) 224 22.68  0.09
Hexenoylglycine (double bond position unknown) 172 23.06  0.07
Hexenoylglycine (double bond position unknown) 172 24.53  0.05
Hydroxyphenylpropionylglycine (hydroxyl position unknown) 224 28.16  0.04
Methylvalerylglycine (methyl position unknown) 174 28.65  0.03
Heptenoylglycine (double bond position unknown) 186 28.71  0.03
Hydroxyoctenoylglycine (hydroxyl position unknown) 216 28.93  0.03
Methylhippuric acid (methyl position unknown) 194 32.58  0.05 [30, 43, 44]
Hydroxyoctanoylglycine (hydroxyl position unknown) 218 33.31  0.04
Octadienoylglycine (double bonds positions unknown) 198 35.07  0.03
Hydroxyoctanoylglycine (hydroxyl position unknown) 218 35.46  0.03
Octadienoylglycine (double bonds positions unknown) 198 36.75  0.03
Sebacylglycine 260 38.12  0.06
Methylhexanoylglycine (methyl position unknown) 188 38.47  0.02
Heptanoylglycine 188 41.07  0.04
Octadienoylglycine (double bonds positions unknown) 198 41.40  0.01
Phenylbutyrylglycine 222 41.61  0.05
Cis-3,4-Methylene-heptanoylglycine 200 42.46  0.02
Octenoylglycine (double bond position unknown) 200 43.38  0.02
Nonenoylglycine (double bond position unknown) 214 47.44  0.01
Nonanoylglycine 216 54.95  0.02
Unknown acylglycines
Unknown #1 210 30.41  0.03
Unknown #2 242 32.90  0.03
Unknown #3 188 35.22  0.03
Unknown #4‡ 258 35.29  0.06
Unknown #5 200 35.45  0.02
Unknown #6 244 36.28  0.03
Unknown #7 256 38.06  0.03
Unknown #8 242 40.27  0.04
Unknown #9 222 50.27  0.04
/MS
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We have developed a method for the comprehensive
analysis of acylglycines in the urine of healthy subjects.
Putative identification of acylglycines was achieved
using retention time information and characteristic
fragmentation patterns. Derivatization or esterification
was not necessary to enhance detection, when using
selective extraction methods like SPE and sensitive
detection instruments like the hybrid QTRAP mass
spectrometer. Greater selectivity and sensitivity were
achieved using MRM scans and simultaneous product
ion scans provide structural elucidation. The use of
optimal acquisition modes is very important. Constant
neutral loss and precursor methods are valuable for
detection of wide range of acylglycines and for the
discovery of expected as well as unexpected, or previ-
ously undetected, acylglycines. Breakdown curves pro-
vided optimal transitions and conditions, as well as
important trends to note for detection of classes of
acylglycines. With this strategy, detection of expected
acylglycines was enhanced and novel acylglycines were
discovered.
A total of 65 acylglycines were detected and of those
only 15 are used for diagnosis of metabolic diseases.
Additional studies need to be done using clinical sam-
ples of subjects with known IEMs or other diseases to
determine the effectiveness of the method in the diag-
noses of these disorders. The dataset generated in this
study will be significant in future research to further
Table 2. Continued
Confirmed acylglycines (n  6)
Unknown #10
Unknown #11
Unknown #12
Unknown #13
*Compounds marked with †are only found in five individuals and those
acylglycines detected in healthy individuals by other methods. The MS
data.
Figure 5. Ion chromatograms from UPLC MS/MS analysis of
urine collected as first morning void from a healthy individual for
5 d. An overlay of total ion chromatograms of multiple reaction
monitoring scans using 62 diagnostic transitions is shown.understand, discover and improve the diagnosis of new
inborn errors of metabolism and other metabolic dis-
eases related to the excretion of acylglycines.
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